Explore the latest news from Khondrion and its team.
NIJMEGEN, the Netherlands – 14 September 2022: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...
NIJMEGEN, the Netherlands – 1 June 2022: Khondrion (or the “Company”), a clinical stage biopharmaceutical company discovering and developing...
NIJMEGEN, the Netherlands – 10 January 2022: Khondrion, a clinical stage biopharmaceutical company discovering and developing therapies targeting...
Enabling continued treatment in 52-week multi-centre study for patients who have completed ongoing KHENERGYZE Phase IIb study investigating...
NIJMEGEN, the Netherlands – 14 October 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...
NIJMEGEN, the Netherlands – 26 August 2021: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting...
1. Tell us about your career before joining Khondrion.I qualified as a Medical Doctor from the University of Utrecht and worked clinically in the...
Cognition is an important function of the brain so we can gain knowledge and understanding. These mental processes include thinking, knowing,...
Classic MELAS syndrome (Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes), MIDD (maternally inherited diabetes mellitus...
1. Tell us all about your career before joining Khondrion I studied pharmacology and molecular biology at the University of Strasbourg in France,...
Chief Executive Officer of Khondrion, Prof. Dr. Jan Smeitink, reflects on the Mitochondrial Medicine conference held from 11-13 December 2019 at the...
Members of the Khondrion team will be attending Mitochondrial Medicine 2019 on 11-13 December 2019. The event will bring together...
